atepeq/tico19 huggingface dataset:
In March, the WHO initiated the "SOLIDARITY Trial" in 10 countries, enrolling thousands of people infected with COVID-19 to assess treatment effects of four existing antiviral compounds with the most promise of efficacy.
ኣብ መጋቢት፡ ውድብ ጥዕና ዓለም (WHO) ናይ ዝተወሃሃደ ``ናይ ሓድነት ፈተነ` ኣብ 10 ሃገራት መስሪቱ፡ ኣብዚ ድማ ኣሽሓት ሰባት ብ ኮቪድ-19 ዝተለኽፉ ክሳተፉ እንከለዉ፡ ነቶም ኣርባዕተ ዓይነት ናይ ጸረ-ቫይረስ ምስ ናቶም ጽልዋታት ተፈቲኖምን ጽቡቕ ውጽኢት ድማ ኣመዝጊቦምን
A dynamic, systematic review was established in April 2020 to track the progress of registered clinical trials for COVID-19 vaccine and therapeutic drug candidates.Vaccine and drug development is a multistep process, typically requiring more than five years to assure safety and efficacy of the new compound.
ብ ሚያዝያ 2020 ሓደ ቅልጡፍ ተዓጻጻፊ ዝኾነ ምርመራ ንምምልካት ገስጋስ ሕክምናዊ ፈተነታት ክታበት ኮቪድ-19ን ንምምዕባል ብዓል ብዙሕ መድረኽ ዝኾነ መድሃኒት፣ ማለት ን ልዕሊ ሓሙሽተ ዓመት ዝወስድ መስርሕ ድሕነት ንኣድማዕነትን እቲ ሓድሽን ጥረነገር ንምርግጋጽ ተጀሚሩ።
Drug development is the process of bringing a new infectious disease vaccine or therapeutic drug to the market once a lead compound has been identified through the process of drug discovery.
ናይ መድሃኒት ምፍራይ መስርሕ ፡ ሓደስቲ ናይ ተመሓላለፍቲ ሕማማት ክታበት ወይ መሕወዪ መድሃኒታት ናብ ዕዳጋ የምጽእ ኣሎ፡ እዚ ድማ ድሕሪ ናይቲ ቀንዲ ጥረ ነገር ነቲ መድሃኒት መርከቢ ምፍላጡ ኢዩ።
It includes laboratory research on microorganisms and animals, filing for regulatory status, such as via the FDA, for an investigational new drug to initiate clinical trials on humans, and may include the step of obtaining regulatory approval with a new drug application to market the drug.
እዚ ድማ ናይ ላባራቶሪ መጽናዕቲ ን ማይክሮኦርጋኒዝምስ ን እንስሳታትን፡ ነቲ ናይ ምጣነ ህላወ ምስማዕ፡ ከም ኣብነት ብ FDA ን ፈተነ ናይ ሓድሽ መድሃኒት ን ሓድሽ ናይ ክሊኒክ ርኽበታት ኣብ ሰባት ንኽህሉ ዝዓለመ፡ ከምኡ’ውን ናይ ፈተነታት ደረጃ ምፍቃድ ምስ ሓድሽ ናይ መድሃኒት ፈተነ ጠለብ፡ ዘጠቓለለ ክኸውን ይኽእል
Development of a COVID-19 vaccine or therapeutic antiviral drug begins with matching a chemical concept to the potential prophylactic mechanism of the future vaccine or antiviral activity in vivo.
ምዕባለ ናይ ኮቪድ-19 ወይ ሕክምናዊ ጸረ ቫይራል መድሓኒት፡ ምስ ምጅማር ከሚካላዊ ኣምር ብምውድዳር ኣቐዲሙ ካብ ሕማም ዝከላኸል ኣገባብ ኽእለት ናይ መጻኢ ክታበት ወይ ጸረ ቫይራል ንጥፈት ኣብ ሂወታውያን (vivo) እዩ።
New chemical entities (NCEs, also known as new molecular entities or NMEs) are compounds that emerge from the process of drug discovery to specify a vaccine or antiviral candidate.
ካብ መስርሕ ዳህሳስ መድሃኒት ዝወጸ ሓድሽ ከሚካላዊ ለዉጢ ባህሪ( NCEs ፡ ከመኡውን ሓድሽ ሞሎክላር ተባሂሉ ዝፍለጥ ወይ NMEs) ተኣኪቡ ካብ መስርሕ ርኽበት ንክታበት ወይ ን ናይ ኣንቲቫይራል ሕጹይ ክፈሊ እዩ።
These have promising activity against a biological target related to COVID-19 disease.
እዚኣቶም ድማ ኣንጻር ናይ ሂወታዊ ዓላማ ዘለዎ ምጽራር ናይ ኮቪድ-19 ፡ ኣዝዩ ውጽኢታዊ ንጥፈታት የካይዱ ኣለዉ።
At the beginning of vaccine or drug development, little is known about the safety, toxicity, pharmacokinetics, and metabolism of the NCE in humans.
ኣብ ናይ መጀመርያ ክታበት ወይ ምዕባለ መድሃኒት ብዛዕባ ዉሕስነት፡ መርዛምነት፡ ፋርማኮኪነቲክስን ናይ NCE መታቦልነት ኣብ ሰባት ዉሑድ ይፍለጥ።
It is the function and obligation of drug development to assess all of these parameters prior to human clinical trials to prove safety and efficacy.
እዚ ምቁጽጻር ናይ መስርሓት ን ኣገባባትን ን ምምዕባል ናይ መድሃኒታት ቅድሚ እቶም ናብ ውልቀ-ሰባት ክትግበሩ ምጅማሮም፡ ክቆጻጸሮም ኣብ ጥዕና ዘምጽ ኦ ሳዕቤን ድማ ክፍትሾምን ግቡእ ናይ መድሂኒት-ምምዕባል ኣካል ኢዩ
A further major objective of drug development is to recommend the dose and schedule for the first use in a human clinical trial ("first-in-human" [FIH] or First Human Dose [FHD], previously also known as "first-in-man" [FIM]).
ካልእ ዝዓበየ ምዕባለ ዓቀን መድሃኒት ፈተነ መደብን ኣብ ደቂሰባት ንመጀመርታ ግዜ ምፍታን እዩ።
In addition, drug development must establish the physicochemical properties of the NCE: its chemical makeup, stability, and solubility.
ከም ተወሳኺ፡ ምዕባለ ፈዉሲ ንፊዩሊከሚካል ንብረት ናይ NCE ፡ እቲ እተሰርሐ ከሚካል፡ ቀዋምነትን ተበራዝነትን ብግዲ ክጅመር ኣለዎ።
Manufacturers must optimize the process they use to make the chemical so they can scale up from a medicinal chemist producing milligrams, to manufacturing on the kilogram and ton scale.
እቶም ናይ ከሚካል መስራሕቲ ካምፓኒታት፡ እቲ ከሚካል ዝሰርሕሉ ኣገባብ ክቅይርዎ ኣለዎም ፡ እዚ ድማ እቶም ናይ ኬምስትሪ ናይ ሕክምና ክኢላታት ካብቲ ብ ሚሊ-ግራም ዝስራሕ ዝነበረ ኣዝዩ ንኢሽተይ ዓቀን ናብ ናይ ኪሎ-ግራማት ን ናብ ቶናትን ክምስርሕሉ ዘኽእል ባይታ ክፈጥሩ ኣለዎም።
They further examine the product for suitability to package as capsules, tablets, aerosol, intramuscular injectable, subcutaneous injectable, or intravenous formulations.
ቀጺሎም ነቲ ፍርያት ን ምቹእነት ናይቲ ፓከጅ ከም ካፕሱል፡ ኣአረስቶል፡ ኢንትራማስኩላር፡ ኢንጀክቲብለ፡ ሱብኮሾስነስ ኢንጀክቲብል፡ ወይ ኢንትራቨንዮን ፎርሙላታት፡ ይምርምርዎም ኢዮም።
Together, these processes are known in preclinical and clinical development as chemistry, manufacturing, and control (CMC).Many aspects of drug development focus on satisfying the regulatory requirements of drug licensing authorities.
ክልቲኦም እዞም መስርሓት ኣብ ቅድመ ክሊኒክን ክሊኒካዊ ምዕባለታት ኣብ ኬምስትርን፣ ምስናዕን ምቁጽጻርን (CMC) ፍሉጣት እዮም። ብዙሓት መለኪዒታት ምምዕባል መድሃኒት ኣብ ምምላእ ድሌታት ብዓል መዚ መድሃኒታዊ ፍቓድ የተኩር።
These generally constitute tests designed to determine the major toxicities of a novel compound prior to first use in humans.
እዚ ሓፈሻዊ ምርመራ ቀንዲ ተጎዳኣነት ናይቲ ባእታ፡ ቅድሚ ኣብ ደቂ ሰባት ምፍታን እዩ።
The Canadian government announced CA$275 million in funding for 96 research projects on medical countermeasures against COVID-19, including numerous vaccine candidates at Canadian universities, with plans to establish a "vaccine bank" of new vaccines for implementation if another coronavirus outbreak occurs.
መንግስቲ ካናዳ ን 96 ናይ መጽናዕቲ መደባት ን ኣንጻር ኮቪድ-19 ዝግበር ዘሎ ናይ ሕክምና ቃልሲ ዝውዕል CA$275 ሚልዮን ከም ዘጽደቀ ኣዊጁ፡ እዚ ድማ ብዙሓት ናይ ክታበት ተወዳደርቲ ኣብ ናይ ካናዳ ዩኒቨርሲታት ምስ መደባት ናይ ።ክታበት ባንክ። ምኽፋት ን ምናልባት ሓዲሽ ዓይነት ኮሮናቫይረስ እንተተላቢዑ ድማ ንምምካትን ፡ ዘጠቃልል ኢዩ።
Clinical trial programs involve three, multiple-year stages toward product approval, and a fourth, post-approval stage for ongoing safety monitoring of the vaccine or drug therapy:
እቶም ናይ ክሊኒክ ናይ ፈተነ መደባት ፡ ን ናይ መወዳእታ ፍቓድ፡ 3 ብዝሐ-ዓመታት ዘለዎም ደረጃታት ፡ ነቶም ቀጸልቲ ናይ ውሕስነት ምቁጹጻር ናይ ክታበትን ናይ መድሃኒት ተራፒን፡ የድልዮ
Phase I trials, usually in healthy volunteers, determine safety and dosing.
ኣብ ናይ ጥዕና ወለንታዉያን፡ ገጽ 1 ፈተነታት፡ ዉሕስነትን ፍወሳን ይምደብ።
Phase II trials are used to establish an initial reading of efficacy and further explore safety in small numbers of people having the disease targeted by the NCE.
ካልኣይ መድረኽ ፈተነ ንዕዉት ዝኾነ ምንባብን ዉሕስነትን ዝሓመሙ ሰባት ሒደት ሰባት ብንሲኢ(NCE) ዝተዓለመ ኢዩ።
Phase III trials are large, pivotal trials to determine safety and efficacy in sufficiently large numbers of people with the COVID-19 infection.
ደረጃ III ፈተነታት ኣዝዮም ዓበይቲ ኮይኖም፡ ኣብቶም ኣዝዮም ብዙሓት ናይ ኮቪድ-19 ልኹፋል መፈተንታታት ናይ ውሕስነት ን ናይ ኣድማዕነታትን ክፈልጥ ዝኽእል ደረጃ ኢዩ።
If safety and efficacy are adequately proved, clinical testing may stop at this step and the NCE advances to the new drug application (NDA) stage to begin marketing.
ውሑስን ኣድማዕን ብምልኣት እንተዝረጋገጽ፡ኣብዚ ደረጃ ክሊኒካዊ መርመራ ምስተቋረጹን NCE ናብ ሓድሽ ምልክታ ዕደጋ (NDA) መድሃኒት ምጀመረን።
Phase IV trials are post-approval trials that may be a condition attached by the FDA, also called post-market surveillance studies.
ገጽ ⵏⴸ ፈተነታት ድሕረ ቅበላ ፈተነታት ብ FDA ኩነታት ዝተታሕዘ እዩ። ቅድመ ዕደጋ ጽኑዕ ሓለዋ መጽናዕትታት ውን ይብሃል እዩ።
In addition to the tests required to move a novel vaccine or antiviral drug into the clinic for the first time, manufacturers must ensure that any long-term or chronic toxicities are well-defined, including effects on systems not previously monitored (fertility, reproduction, immune system, among others).
ከም ተወሳኪ፡ ነዚ ፈተነታት ንክታበት ኖቭል ወይ ጸረ-ቫይራል መድሃኒት ንመጀመርታ ግዜ ናብ ክሊኒክ ክንቀሳቅስ ጠሊቡ።ሰራሕቲ ዝኮነ ነዊሕ ግዜ ወይ ሕዱር መርዛምነታት ዘለዎ ኣጸቢቁ ከምዝተጸንዐ ከዉሕሱ ኣለዎም፡ ንጽልዋ ኣብ ስርዓታት ኣቀዲሙ ዝተቆጻጸረ (ፍርያምነት፡ምድቃል፡ስርዓት ነዝዓ ኣብ መንጎ ካልኦት) የማእክል።
In the United States, this process is called a "new drug application" or NDA.
ኣብ ሕቡራት መንግስታት፡ እዚ መስርሕ "ሓድሽ መድሃኒት ምዉዐላ" ወይ NDA ይባሃል።
A clinical trial design in progress may be modified as an "adaptive design" if accumulating data in the trial provide early insights about positive or negative efficacy of the treatment.
ክሊኒካዊ ፈተነ ዝተሰርሐ ኣብ ዕቤት ክማሓየሽ ይኽእል ከም "ዘለማምድ መስርሕ" እንተ ድኣ እኩብ ሓበሬታ ኣብ ፈተነ ዘሎ ኣቀዲሙ ብዛዕባ ኣወንታን ኣሉታን ኣድማዕነት ናይ ፍወሳ ሂቡ።
The global Solidarity and European Discovery trials of hospitalized people with severe COVID-19 infection apply adaptive design to rapidly alter trial parameters as results from the four experimental therapeutic strategies emerge.
ዓለምለኻዊ ስምረትን ናይ ኤውሮጳውያን ድህሰሳ ፈተነታት ናይ ኣብ ሕክምና ዝእለዩ ሕሙማት ሰባት ምስ ጽንኩር መልከፍቲ ኮቪድ-19 ልሙድ ቅርጺ ብምምልካት ን ፍጡን መኸተ ፈተና ፓራመተር፡ከም ውጽኢቱ ኣርባዕተ ግዝኣት ምኮራ ተቐልቂሉ።
Adaptive designs within ongoing Phase II-III clinical trials on candidate therapeutics may shorten trial durations and use fewer subjects, possibly expediting decisions for early termination or success, and coordinating design changes for a specific trial across its international locations.
እቲ ዝተወሃሃደ ንድፊ ኣብቲ ቀጻልነት ናይ ገጽ II-III ናይ ክሊኒክ ፈተነታት ፡ነቲ ናይቶም ተወዳደርቲ ተራፒስትስ ናይ ፍረተነ ኣንፈት ከሕጽሮን ውሑድ ነገርት ክጥቀሙን የኽእል፡ እዚ ድማ ወይ ቀልጢፎም ክዕወቱ ወይ ድማ ክወድቁ ይሕግዝ ፡ ቀጺሎም ውን ሓደ ዝተወሃሃደ ፍሉይ ን ዓለምለኻዊ ዝርግሐ ዝዓለመ ንድፊ ከዳልዉ ይሕግዝ
Most novel drug candidates (NCEs) fail during drug development, either because they have unacceptable toxicity or because they simply do not prove efficacy on the targeted disease, as shown in Phase II-III clinical trials.
ዝበዝሑ ካብቶም ኣደነቅቲ ናይ መድሃኒት ውጽኢታት(NCEs)፡ ኣብ ናይ መድሃኒት መስርሕ ከለዉ ውዱቃት ኮይኖም፡ እዚ ድማ ብሰንኪ ናቶም መርዛምነት ወይ ድማ ብቀሊሉ ነቲ ዝተደልየ ታርገት ኵአቅዑ ብቁዓት ኮይኖም ስለ ዝተረኽቡ፡ እዚ ድማ ኣብ ደረጃ II-III ናይ ክሊኒክ ፈተነታት ኢዩ።
The high failure rates associated with pharmaceutical development are referred to as an "attrition rate", requiring decisions during the early stages of drug development to "kill" projects early to avoid costly failures.
እቲ ዝላዓለ መጠን ዉድቀት ምስ ፋርማስያዊ ምዕባለ ዝተሓሓዝ “መጠን ምሕላል” ከም ዘመልክት ይጥቀስ፡ክሳራታት ዋጋ ንምእላይ፡ ኣብቲ መጀመርያ ደረጃ ምዕባለ ከኒና፡ ን ``ምቕታል`` ፕሮጀክትታት ክቛረጽ ዉሳኔ ክውሰድ ኣለዎ።
One 2010 study assessed both capitalized and out-of-pocket costs for bringing a single new drug to market as about US$1.8 billion and $870 million, respectively.
ሓደ 2010፡ መጽናዕቲ ክልቲኡ ናብ ርእሰማል ዝተለወጠን ካብ ጁባ ዝወጽእ ዋጋታት ንጽል ሓድሽ መድሃኒትን ናብ ዕዳጋ ንምምጻእ ከባቢ US$1.8 ቢልዮን ን $870 ሚልዮን ተኸታቲሉ ምዃኑ መርሚሩ።
A median cost estimate of 2015-16 trials for development of 10 anti-cancer drugs was $648 million.
እቲ ማእከላይ ዋጋ ምምዕባል ናይ 10 ጸረ-ካንሰር መድሃኒት ፡ኣብ 2015-16፡ 648 ሚሊዮን ዶልር ኢዩ።
In a 2016 review of 106 drug candidates assessed through clinical trials, the total capital expenditure for a manufacturer having a drug approved through successful Phase III trials was $2.6 billion (in 2013 dollars), an amount increasing at an annual rate of 8.5%.
ኣብ 2016፡ 106 ናይ መድሃኒት ሑጹያት ንሕክምናዊ ፈተነ ክሳብ ሳልሳይ መድረኽ 2.6 ቢልዮን ዶላር (ካብ 2013) ከም ዝሰልዕ ብ 8.5 ሚእታዊት ድማ ዓመታዊ ይዉስኽ
Seven trials were evaluating repurposed drugs already approved to treat malaria, including four studies on hydroxychloroquine or chloroquine phosphate.
እቲ ኣቐዲሙ ዓሶ ንምፍዋስ ተቀባልነት ዝረኸበ፡ዳግመ ምደባ መድሃኒታት እቶም ሸዉዓተ ፈተነታት ይግምገሙ ነይሮም።ኣርባዕተ መጽናዕትታት ዘማእከለ ኣብ ሃይድሮስይክሎሮኪን (hydroxychloroquine) ወይ ክሎሮኪን ፎስፈይት።
Repurposed antiviral drugs make up most of the Chinese research, with 9 Phase III trials on remdesivir across several countries due to report by the end of April.
ኩሉ ናይ ቻይና ምርምር ዕላማ ዘለዎ መድሃኒት ንምስራሕ እዩ። 9 መድረኻት ሰለስት ፈተናታት ኣብ መወዳእታ ሚይዝያ ናብ ገለ ሃገራት ክሕበር እዩ።
Led by the Bill and Melinda Gates Foundation with partners investing US$125 million and coordinating with the World Health Organization, the COVID-19 Therapeutics Accelerator began in March, facilitating drug development researchers to rapidly identify, assess, develop, and scale up potential treatments.
ብ ቢልን መሊንዳን ጌትስ ምስ ብጾቶም ዝምራሕ ትካል ሬዲኤት 125 ሚሊዮን ዶላር ምስ ምትሕብባር ዓለማዊ ዉድብ ጥዕና (WHO) ከም ዘዋፈሩ ይፍለጥስነ ምፍዋስ ኮቪድ 19 ኣብ መጋብት ምቅልጣፍ ኣርእዩ ከም ኣቃላጠፍቲ ምስራሕ መድሃኒት ተመራመርቲ ፡ቀልጢፎም ኣለለልዮም፡ ገምጊሞም፡ ኣማዕቢሎም፡ ለኪዖም ብቁዕ ዝኮነ መድሃኒት ጀሚሮም
The COVID-19 Clinical Research Coalition formed to coordinate and expedite results from international clinical trials on the most promising post-infection treatments.
እቶም ናይ ክሊኒካል ልፍንቲ ናይ መጽናዕቲ ጉጅለ ናይ ኮቪድ-19 ካብቲ ዘካይድዎ ዘለዉ ናይ ምርምራት ብውጺታት፡ ኣብቲ ድሕረ-ለበዳ ናይዚ መርመራታት ውጽኢት ዝተተግበረሉ ተስፋ ዘለዎ ቦታታት ፡ ጽቡቕገስጋስ ከም ዝገበሩ ተረዲኦም
In early 2020, numerous established antiviral compounds for treating other infections were being repurposed or developed in new clinical research efforts to alleviate the illness of COVID-19.
ኣብ መጀመርታ ናይ 2020፡ ኣዝዮም ብዙሓት ሕውስዋሳት ዝተኸናወኑ ጸረ-ቫይረሳት ፡ ካልኦት ረኽስታት ንምሕዋይ ዕላማ ከም እንደገና ከም እተጀመሩ ን፡ ኣብ ሓድሽ ናይ ክሊኒክ መጽናዕቲታት ጻዕሪታት ን ምፍካስ ናይ ኮቪድ-19 ከምዝማዕበሉን ተፈሊጡ
For an already-approved drug (such as hydroxychloroquine for malaria), Phase III-IV trials determine in hundreds to thousands of COVID-19-infected people the possible extended use of an already-approved drug for treating COVID-19 infection.
ከም በዓል ሃይድሮሲክሎሮክ፡ ኣቀዲሙ ቁቡል ዝኮነ ናይ ዓሶ መድሃኒት ሳልሳይን ራባዓይን ፈተነ ኣብ ኣማኢታት ክሳብ ኣሻሓት ብ ኮቪድ-19 ዝተለኸፉ ሰባት ብዝተናወሐ ተጠቃምነት ናይቲ ኣቀዲሙ ዝጸደቐ መድሃኒት ናይ ኮቪድ-19 ለበዳ ክሕከሙሉ ከም ዝክእሉ ኣኽኢሉ
As of early April 2020, 103 candidate therapeutics were in preclinical or a stage of Phase I-IV development, with trial results for 29 drug candidates expected during April.
ክሳብ 2020 መጋቢት ፡103 ተወዳደርቲ ናይ ተራፐውቲክስ (ናይ መድሃኒት ምፍራይ ክኢላታት) ኣብቲ ናይ ቅድመ ክሊኒክ ደረጃ ወይ ደረጃ ናይ ገጽ ምዕባለ ካብ I-IV በጺሖም፡ ክሳብ መወዳእታ መጋቢት ድማ 29 ተናሓናሕቲ ወይ ተወዳደርቲ ናይ መድሃኒታት ትጽቢት ይግበረሎም
In March, the World Health Organization (WHO) launched the coordinated "Solidarity trial" in 10 countries to rapidly assess in thousands of COVID-19 infected people the potential efficacy of existing antiviral and anti-inflammatory agents not yet evaluated specifically for COVID-19 illness.
ኣብ መጋቢት፡ ማሕበር ጥዕና ዓለም (WHO)፡ ሓደ ዝተወሃሃደ ``ናይ ሓድነት ፈተነ` ኣብ 10 ሃገራት መስሪቱ፡ ዕላምኡ ድማ፡ ነቲ ቅድሚ ሕጂ ተሰሪሕሉ ዘይፈልጥ ምምዕባል ናይ ጸረ-ነፍሳትን ጸ-ነድርና ናይ ኮቪድ-19 ዝተባህለ ዓይነት ተላባዒ ሕማም ብ ኣድማዕነት ንምምካት ኮይኑ፡ ካብ ዝተለኽፉ ሰባት ቅምሶታት ንምውሳድ ድማ ክተሓባበራ ተባሂሉ ዝተወደበ ኢዩ
Do any of the drugs reduce mortality?
ካብዞም ዝተፈላለዩ መድሃኒታት ነቲ ናይ ዘይሙማት ግዚያት የጉዱልዎ ዲዮም፥
Do any of the drugs reduce the time a patient is hospitalized?
ሓደ ሕ ሙ ም ኣብ ሆስፒታል ዝጸንሓሉ ግዜ ዝኾ ነ መ ድሃኒትየሕጽሮ’ዶ?
Do the treatments affect the need for people with COVID-19-induced pneumonia to be ventilated or maintained in intensive care?
እቲ ን ተሓከምቲ ናይ ኮሮና-ቫይረስ ዝወሃብ ክንክን ናይ ኒሞንያ ቨንቲለሽን ክዳለወሉ የድልዮ ዲዩ፤
Could such drugs be used to minimize the illness of COVID-19 infection in healthcare staff and people at high risk of developing severe illness?Enrolling people with COVID-19 infection is simplified by using data entries, including informed consent, on a WHO website.
እዚ መድሃኒታት እዚ ን ናይ ኮቪድ-19 ምስፍሕፋሕ ፡ ነቶም ኣብ ናይ ጥዕና ቦታ ዝሰርሑን፡ ኣብዚ ቫይረስ ዘለዎ ቃልዕ ቦታ ዝነብሩን፡ ከጉድሉ ይከኣል ዲዩ፥ ነቶም ብ ኮቪድ-19 ዝተለኽፉ ሰባት ምምዝጋብ በቲ ናይ ውድብ ጥዕና ዓለም ናይ መዝገብ ሓበሬታ ብምጥቃም ክቃለል ይኽእል ኢዩ
After the trial staff determines the drugs available at the hospital, the WHO website randomizes the hospitalized subject to one of the trial drugs or to the hospital standard of care for treating COVID-19.
ድሕሪ እቶም ናይ ፈተንቲ ነቲ መድሃኒት ኣብ ሕክምና ከም ዘሎ ምርግጋጾም፡ እቲ ውድብ ጥዕና ዓለም (WHO) ነቶም ኣገደስቲ ዝበሃሉ መድሃኒታት ኣብ ግቡእ ተጠቃምነት መታን ክረኽቡ ኣብ ወብሳይቱ ኣቀሚጥዎም ይርከብ
The trial physician records and submits follow-up information about the subject status and treatment, completing data input via the WHO Solidarity website.
ኩሉ ናይ ሓካይም ፈተነን ዝተረክበ ሓቤሬታን ብዛዕባ ዘሎ ኩነታት መድሃኒትን ብ ዉድብ ዓለማዊ ጥዕና(WHO) መርበብ ኢዩ ዝመሓላለፍ።
A global safety monitoring board of WHO physicians examine interim results to assist decisions on safety and effectiveness of the trial drugs, and alter the trial design or recommend an effective therapy.
ሓፈሻዊ ናይ ውሕስነት ኣማሓደርቲ ናይ ውድብ ጥዕና ዓለም (WHO) ፊዚሽያናት፡ ነቲ ግዚያዊ ውጽ ኢት ተመራሚሮምሉ፡ እዚ ድማ ነቲ ናይ መድሃኒታት ፈተነታት ንክጸፍፍን ቀጻሊ ዝኾነ ኣወንታዊ ለውጢ ንኸምጽእን ኸምኡውን ሓፈሻዊ ውጺታውነት ንክዓቢን ፡ ዝሕግዝ ኢዩ፡፡
A similar web-based study to Solidarity, called "Discovery", was initiated in March across seven countries by INSERM (Paris, France).During March, funding for the Solidarity trial reached US$108 million from 203,000 individuals, organizations and governments, with 45 countries involved in financing or trial management.
ኣብ ሓደ ዓይነት መርበብ ዝተመርኮሰ መጽናዕቲ ኣብ ሕብረት"ድህሰሳ"ተባሂሉ።እዚ ኣብ መጋቢት 7 ሃገራት ዘማእከለ ብኢንሰርም(ፓሪስ፡ፍራንስ) ተተባቢዑ ኔሩ። እቲ ኣብ መጋቢት ንሕብረት ፈተና ዝተወፈየ ገንዘብ US $108,000,000 ዶላር በጺሑ፡እዚ ካብ 203,000 ውልቀ ሰባት፡ውድባት፡መንግስትታትን ምስ 45 ሃገራት ኣብ ምሕደራ ገብዘብ ወይ ምሕደራ ፈተነ የማእክል።
Numerous candidate drugs under study as "supportive" treatments to relieve discomfort during illness, such as NSAIDs or bronchodilators, are not included in the table below.
ዝፍአላለየ ናይ መድሃኒት ሕጹያት ኣብ መጽናዕቲ ዘለዉ ንዘይ ምቹእነት ኣብ ግዜ ሕማም ጠቀምቲ እዮም ከም በዓል ኤን ኤስ ኤይድስ ወይ ብሮንኮዲላቶርስ ኣብ ታሕቲ ኣይተጠቅሱን።
Others in early-stage Phase II trials or numerous treatment candidates in Phase I trials, are also excluded.
ካልኦት ኣብ ናይ መጀመርያ-ደረጃ ገጽ- II ፈተነታት ወይ ብዙሓት ናይ ገጽ- II ተወዳደርቲ ተኣልዮም ኢዮም
Drug candidates in Phase I-II trials have a low rate of success (under 12%) to pass through all trial phases to gain eventual approval.
ሕጹያት መድሃኒታት ኣብ ገጽ I-II ተፈቲኖም ትሕቲ 12% ዘምጽኡ፡ኩሎም ገጻት ፈተነታት ሓሊፎም ኣብ መወዳእታ ፍቓድ ክረኽቡ ትሑት መጠን ዓወት ኣለዎም።
Hydroxychloroquine is more commonly available than chloroquine in the United States.
ኣብ ሕቡራት መንግስታት ኣሜርካ ሃይድሮክሲክሎሮኪን ካብ ክሎሮኪን ዝበዝሐ ቀረብ ኣሎ።
Although several countries use chloroquine or hydroxychloroquine for treatment of persons hospitalized with COVID-19, as of March 2020 the drug has not been formally approved through clinical trials in the United States.
ወላ እካ ብዙሓት ሃገራት ክሎሪን ወይ ህይድሮክሎሮኪን ከም መድሃኒት ናይ ኮቪድ-19 ይጥቀማሉ እንተለዋ፡ እዚ መድሃኒት እዚ ክሳብ መጋቢት-19 ኣብ ዘሎ ግዜ፡ ኣብ ሕቡራት መንግስታት ኣሜሪካ ዝኾነ ናይ ሕክምና ኣፍልጦ ኣይረኸበን ዘሎ።
Chloroquine has been recommended by Chinese, South Korean and Italian health authorities for the treatment of COVID-19, although these agencies and the US CDC noted contraindications for people with heart disease or diabetes.
ዋላ'ኳ እዞም ወኪላትን ሕቡራት መንግስትታትን CDC ምስ ሕማም ልብን ሽኮርን እቲ መድሃኒት ተጓዳኢ ክኸውን ከምዝኽእል ዘአምት ምልክት ንህዝቢ እንተሃቡ፡ክሎሮኲን ኣብ ቻይና፡ደቡብ ኮርያን ጣልያንን ናይ ጥዕና ባዓል መዚ ኮቪድ-19 ንምክልኻል ተላብዮም።
Both drugs have extensive interactions with prescription drugs, affecting the therapeutic dose and disease mitigation.
ክልቲኦም መድሃኒት ሰፊሕ ኣተጋባብራ ምስ ኣወሳስዳ መድሃኒትን ስነ ፈዉሲ ከኒናን ሕማም ፈዉሲ ይጸልዎ።
Some people have allergic reactions to these drugs.On 12 April, a preliminary clinical trial conducted at a hospital in Brazil was stopped when several people given high doses of chloroquine for COVID-19 infection developed irregular heart rates, causing 11 deaths.
ገለገለ ሰባት ንዞም ዓይነት መድሃኒት ኣለርጂክ ኣለዎ። ኣብ 12 ሚያዝያ ናይ መባእታዊ ሕክምና ፈተነ ኣብ ብራዚል ኣካይዳ እካ እንተ ነበረ ግና ቡዙሕ ዓቀን ክሎሮኪን ንለበዳ ኮቪድ-19 ንዝሓመሙ ዘይስሩዕ ናይ ልቢ ህርመት ስለዘምጸኣሎም ኣቃሪጻቶ፣ በዚ ምኽንያት ከኣ 11 ሰባት ሞይቶም።
Chinese clinical trials in Wuhan and Shenzhen claimed to show that favipiravir was "clearly effective".
ናይ ቻይና ሕክምናዊ ፈተነታት ኣብ ዉሃንን ሸንዝሀንን ፋቪፒራቪራ(favipiravir) ብርጉጽ ውጻኢታዊ ከምዝኾነ ንኸርእያ ሓቲተን።
Of 35 patients in Shenzhen tested negative in a median of 4 days, while the length of illness was 11 days in the 45 patients who did not receive it.
ካብቶም ተሓከምቲ እቶም 35 ብ ማእከላይ ገምጋም ኣብ ውሽጢ 4 መዓልታት ብ ኣሉታ ተመርሚሮም፡ በንጻሩ ንውሓት ናይቲ ሕማም ኣብቶም 45 ተሓከምቲ 11 መዓላት ጥራይ ኔሩ።
In a study conducted in Wuhan on 240 patients with pneumonia half were given favipiravir and half received umifenovir.
ኣብ ዉሃን ኣብ 240 ሰባት ከም ዝተጸንዐ ፍርቆም ፋቪፒራቪር (Favipiravir) ፍርቆም ድማ ኡሚፌኖቪር (Umifenovir) ተዋሂቦም
The term "preclinical research" is defined by laboratory studies in vitro and in vivo, indicating a beginning stage for development of a vaccine, antiviral or monoclonal antibody therapy, such as experiments to determine effective doses and toxicity, before a candidate compound is advanced for safety and efficacy evaluation in humans.
ቅድመ ሕክምና ምርምር ላባላቶሪ መጽናዕቲ ኣብ ቪትሮን ቪቮን ናይ መጀመርታ ደረጃ ምዕባለ ክታበት ኣንጻር ቫይረስ ወይ ንጽለ መነጸር ጸረ ኣካል ሕክምና፡ ንኣብነት ፈተነ ውጽኢታው ዓቀንን ተጓዳእነትን ንውሕስነት ውጽኢታዊ ገምጋም ኣብ ደቂ ሰባት።
Some antibiotics may be repurposed as COVID-19 treatments:
ገለ ገለ ጸረ-ነፍሳት ፡ ኮቪድ-19 ንምፍውስ ክንጥቀመሎም ንኽእል ኢና።
In March 2020, the main protease of the SARS-CoV-2 virus was identified as a target for post-infection drugs.
ኣብ መጋቢት 2020፡ እቲ ቀንዲ ፕሮቲስ ናይ SARS-CoV-2 ቫይረስ ፡ ከም ናይ ድሕረ መልከፍቲ መድሃኒት ምስራሕ ዕላማ ተፈሊጡ።
This enzyme is essential to the host cell to reproduce the ribonucleic acid of the virus.
እዚ ኢንዛይም ነቲ ኣኣንጋዲ ኣህዮ ሪቦኒክሊክ (ribonucleic) ኣሲድ ንክፈጥር ኣዝዩ ኣገዳሲ ኢዩ።
To find the enzyme, scientists used the genome published by Chinese researchers in January 2020 to isolate the main protease.
ምራቕ ንምርካብ፡ ስነ-ፍልጠታውያን ንዝተሓትመ ጂኖም ይጥቀሙ፡እዚ ቻይናውያን ተመራመርቲ ኣብ ጥሪ 2020 ንቐንዲ ፕሮቲዝ ንምፍላይ ተጠቂሞምሉ።
As a potential combination therapy, they are used together in two Phase III arms of the 2020 global Solidarity project on COVID-19.
ከም ኣገዳሲ ምውህሃድ ናይ ተራፒ፡ ኣብ ክልተ ደረጃታት III ኣእዳው ናይ ዓለማዊ ናይ ኮቪድ-19 ሓድነት ፕሮጀችት 2020 ይጥቀሙ ኢዮም።
A preliminary study in China of combined lopinavir and ritonavir found no effect in people hospitalized for COVID-19.
ቅድመ መጽናዕቲ ኣብ ቻይና ድምር ናይ ሎፒናቪርን ሪቶናቪርን(lopinavir and ritonavir) ኣብ እቶም ተኣለይቲ ሕሙማት ኮቪድ-19 ወላሓንቲ ጽልዋ ከምዘይረኸበ ኣረዲኡ።
b'Drug repositioning (also known as drug repurposing, re-profiling, re-tasking or therapeutic switching) is the repurposing of an approved drug for the treatment of a different disease or medical condition than that for which it was originally developed.
ቢ መድሃኒት ዳግም ቦታ ዝሓዘ (ዳግም ዕላማ ዝተዋህቦ ተባሂሉ’ውን ይጽዋዕ፡ ዳግም ቅርጺ፡ ዳግም ዕማም ወይ ድማ ፍወሳዊ መቐይሮ) ዝበሃል ሓደ ዳግም ዕላማ ን ሓደ ፍቁድ መድሃኒት ናይ ዝተፈላለዩ ሕማማት ወይ ድማ ሕክምናዊ ኩነት ካብቲ መበቖላዊ ዝማዕበለሉ ዝፍውስ እዩ።
This is one line of scientific research which is currently being pursued to develop safe and effective COVID-19 treatments.
ሓደ መንገዲ ናይ ሰለ-ፍልጠት ተመራመርቲ ዉሑስን ውጽኢታውን መድሃኒት ናይ ኮቪድ-19 ንምስራሕ እዩ
Other research directions include the development of a COVID-19 vaccine and convalescent plasma transfusion.SARS-CoV-2 has about 66 druggable proteins, each of which has multiple ligand binding sites.
ካልኦት ናይ መጽናዕቲ ኣንፈታት ድማ እዚ ይመስል፡ ን ናይ ኮቪድ-19 ክታበት ምምዕባል ን ጸማልያዊ ፕላስማ ምምሕልላፍ ናይ SARS-CoV-2 ፡ እዚ ድማ 66 ናይ መድሃኒታት ፕሮቲናት ዝሓዘ ኮይኑ፡ ነፍሲ ወከፎም ድማ ዝተባዝሐ ሊጋንድ ከም መላግቦናይ ሳይት ይሕዙ
Analyzing those binding sites provide the reasonable project of developing effective antiviral drug against COVID-19 proteins.
ነዞም ቦታታት መሸፈኒ ምምርማር፡ናይ ምምዕባል ዉጺኢታዊ ጸረ-ቪራል መድሃኒት ኣንጻር ኮቪድ-19 ፕሮቲናት ምክንያታዊ ፕሮጀክት የቕርብ።
Of the most important SARS-CoV-2 target proteins are papain-like protease, RNA dependent RNA polymerase, helicase, S protein, and ADP ribophosphatase.
ካብ ኩሉ ኣገዳሲ ሳርስ-ኮቭ -2(SARS-CoV-2) ዕላማ ዝኾ ኑ ፕሮቲናት ፓፐይን ዓይነት ፕሮቴዝ፣ ኣርኤንኤይ(RNA) ጽግዕተኛ፣ኣርኤንኤይ(RNA) ፖሊመረዝ፣ ሀሊኬዝ፣ኤስ ፕሮቲን፣ኤዲፒ ( ADP)ሪቦፎ ስፌት
Hussein A A, et al studied several candidate compounds which then optimized and analyzed for their skeleton similarity with the highest similar approved drugs in order to accelerate a potent anti-SARS-CoV-2 drug development in his preclinical study to be recommended in a clinical study design.
ሑሴን ን ካልኦትን (Hussein A A, et al) ብዙሓት ድርብራብ ተወዳዳሪ፡ ካብ ሽኡ ን ኣስከሬኑ ተመሳሳሊ ኣዕጋቢን ኣጽናኦ። እዚ ዝላዓለ ተመሳሳሊ ተቀባልነት ዘሎዎ መድሃኒት፡ ምእንቲ ኣንጸር-SARS-CoV-2 መድሃኒት ምምዕባል ቅድመ ክሊኒካል መጽናዕቲ ከፍልጥ ኣብ ክሊኒካል መጽናዕቲ ስርሓቱ ተማሕጺኑ።
Chloroquine is an anti-malarial medication that is also used against some auto-immune diseases.
ክሎሮኪን ናይ ዓሶ መድሃኒት ኢዩ፡ ካብ ነብሰ መጥቃዕቲ ሕማም’ዉን ንጥቀመሉ ኢና።
On 18 March, the WHO announced that chloroquine and the related hydroxychloroquine would be among the four drugs studied as part of the Solidarity clinical trial.
ኣብ መጋቢት 18፡ ውድብ ጥዕና ዓለም (WHO) ክሎሮኲንን ምስ ሃይድሮክሲክሎሮኲን (hydroxychloroquine) ዝተሓሓዝን ኣብ መንጎ እቶም ኣርባዕተ ዝተጸንዑ ኣፋዉስ ከም ክፋል ናይ ሕብረት ክሊኒካዊ ፈተነ ክኾኑ ከም ዝኽእሉ ኣዉጁ።
New York governor Andrew Cuomo announced that New York State trials of chloroquine and hydroxychloroquine would begin on 24 March.On 28 March, the FDA authorized the use of hydroxychloroquine sulfate and chloroquine phosphate under an Emergency Use Authorization (EUA).
ኣማሓዳሪ ኒው-ዮርክ ኣንድሪው ኩሞ ከም ዝሓበሮ፡ ናይ ነው-ዮርክ ፈተነ ናይ ክሎሮኪን ንህይድሮጽዮክሎሮኪን ፈተነታት ካብ 24 መጋቢት ጀሚሩ ክትግበር ኢዩ። ኣብ 28 መጋቢት፡ FDA ን ተጠቃምነት ናይ ንህይድሮጽዮክሎሮኪን ሱልፋይትን ክሎሮኪን ፎስፈይትን፡ ኣብ ትሕቲ ናይ ኢመርጀንሲ ጥቕሚ ናይ ፍቃድ (EUA)፡ ኣብ ጥቕሚ ኵዕሉ ከም ዝጂምሩ ኣፍሊጡ።
The treatment has not been approved by the FDA's clinical trials process and is authorized under the EUA only as an experimental treatment for emergency use in patients who are hospitalized but are not able to receive treatment in a clinical trial.
እዚ ክንክን ሕክምና ብ FDA ናይ ክሊኒክ መፈተኒ መስርሕ ፍቓድን ኣፍልጦን ኣይረኸበን፡ ኣብ ትሕቲ EUA ጥራይ ከም ናይ መፈተኒ ናይ ሕክምና ክንክን ን ቅልጡፍ ረድኤት ዝደልዩ ተሓከምቲ ናይ ሆስፒታል ኢዩ ዝወሃብ፡ ኣብ ክሊኒካት ግን ኵአሃብ ኣይፍቀድን ኢዩ።
The CDC has said that "the use, dosing, or duration of hydroxychloroquine for prophylaxis or treatment of SARS-CoV-2 infection" are not yet established.
ሲዲሲ(CDC)፡ ዓቀንን ንዉሓትን ሃይድሮክሲክሎሮኪን ንፍወሳ ሳርስ ኮቭ ክልተ(SARS-COV_2) ለበዳ መልእኽቲ ኣየማሓላለፈን ዘሎ።
Doctors have said they are using the drug when "there's no other option".
ሓካይም ነቲ መድሃኒት ኣማራጺ ክንስእን ከለና ንጥቀመሉ ኣለና ኢሎም።
A Turkish research team in Istanbul is conducting a small study on the use of chloroquine in combination with zinc, vitamin A, vitamin C and vitamin D.
ናይ ቱርኪ ተመራመርቲ ኣብ ኢስታንቡል ንእሽተይ መጽናዕቲ ክሎሮኪን ምስ ዚንክ፡ ቫይታሚን ኤይ፡ ሲን፡ ዲ፡ ሓዊሶም ኣካዪዶም።
Large studies are underway at Duke University and the University of Oxford.
ኣብ ኦክስፎርድን ዱክ ዩኒቨርሲቲ፡ሰፊሕ መጽናዕቲ ይካየድ ኣሎ።
NYU Langone Medical School is conducting a trial on the safety and efficacy of preventative use of hydroxychloroquine.
NYU ላንጎን ቤት ትምህርቲ ሕክምና ፈተነ ኣብ ዉሕስነትን ኣድማዕነትን ናይ ተኸላኸሊ ጥቕሚ ሃይድሮሲክሎሮኪ (hydroxychloroquine)ን ፈተነ ኣካይዱ።
Chinese clinical trials in Wuhan and Shenzhen claimed to show favipiravir was "clearly effective".
ኣብ ዉሃንን ሸንዝህንን ናይ ቻይና ክሊኒካዊ ፈተነታት ፋቪፒራቪር “ብዘይዉሉዉል ዉጺኢታዊ” ከም ዝነበረ ከርኢ ጠሊቡ።
35 patients in Shenzhen tested negative in a median of 4 days, while the length of illness was 11 days in the 45 patients who did not receive it.
35 ተሓከምቲ ኣብ ሸንዘን ብ ኣሉታ ተመርሚሮም ኣብ ውሽጢ 4 መዓልታት፡ ወላካ እቲ ንውሓት ግዜ ፡ናይቲ ሕማም ኣብቶም ዘይተቀበሉ ፡ 11 መዓልታት ኣብ 45 ተሓከምቲ እንተነበረ።
In a study conducted in Wuhan on 240 patients with pneumonia, half were given favipiravir and half received umifenovir.
ኣብ ዉሃን 240 ሕሙማት ኒሞንያ ፍርቆም ፋቪፕራቪር( Favipiravir) ፍርቆም ድማ ኡሚፈኖቪር (Umifenovir) መድሃኒት ከም ዝተዋሃቡ ይፍለጥ።
The Italian Pharmaceutical Agency reminded the public that the existing evidence in support of the drug is scant and preliminary.
ናይ ዓዲ ጣልያን ናይ ፋርማሲ ወኪል፡ እዚ ወጽዩ ዘሎ መረጋገጺ ን መድሃኒት መጠቀሚ ኣዝዩ ውሑድን ፡ ጀማሪ ዙርያ ሙኻኑ ነቶም ህዝቢ ኣፍሊጡ።
On 2 April, Germany announced that it would purchase the drug from Japan for its stockpile, and use the military to deliver the drug to university hospitals, where the drug will be used to treat COVID-19 patients.
ኣብ 02 ሚያዝያ ጀርመን ካብ ጃፓን መድሃኒት ገዚኣ ከም ዝኣከበት ወተሃደራዊ ሰርዊት ገይራ ድማ ናብ ዪኒቨርሲቲ ሕክምና ከም ዘብጽሓቶ፡ ንሱ ድማ ፈዉሲ ናይ ኮቪድ 19 ከምዝኮነ ሕቢራ ነይራ።
According to the South China Morning Post, Shinzo Abe has made overtures to the Trump administration about purchasing the drug.The drug may be less effective in severe cases of illness where the virus has already multiplied.
ጋዜጣ ደቡብ ቻይና ከምዘመልክቶ, ሺንዞኣበ (Shinzo Abe) ን ናይ ምምሕዳር ዕደጋ መድሃኒት ዝኸውን መኽፈቲ ሙዚቃ ጥሩምባ ነፊሑ ወይ ድማ ፍቃድ ሂቡ፡ ቫይረስ ኣቐዲሙ ስለዝተባዘሐ እቲ መድሃኒት ንጽንኩር ኩነታት ሕማም ዘይውጽኢታዊ ክኸውን ይኽእል እዩ።
It may not be safe for use by pregnant women or those trying to conceive.
ብ ጥንስቲ ሰበይቲ ምጥቃም ወይ ንምጥናስ ዝፍትኑ ዉሑስ ከይከውን ይኽእል እዩ።
One study of lopinavir/ritonavir (Kaletra), a combination of the antivirals lopinavir and ritonavir, concluded that "no benefit was observed".
ሓደ መጽናዕቲ ናይ ላፒናቪር/ሪቶናቪር (Kaletra)፡ ምትሕውዋስ ናይ ጸረ-ቫይረስ ላፒናቪርን ሪቶናቪር ን ``ዝኾነ ጥቅሚ ከም ዘይሃበ`` ደምዲሙ።
The drugs were designed to inhibit HIV from replicating by binding to the protease.
እዚ መድሃኒታት ን HIV ምእንቲ ከይባዛሕ ብምእሳር ንፕሮቲዝ ክኽልክል ተመስሪሑ ነይሩ።
A team of researchers at the University of Colorado are trying to modify the drugs to find a compound that will bind with the protease of SARS-CoV-2.There are criticisms within the scientific community about directing resources to repurposing drugs specifically developed for HIV/AIDS.
ኣብ ኮሎራዶ ዪኒቭርሲቲ ሓንቲ ናይ መጽናዕቲ ጋንታ ነቲ መድሃኒት ንምምሕያሽን ከምኡውን መታሓውስቲ (compound) ዘዐውር ምስኣብቲ ናይ ሳይንሳዊ ኮሚኒቲ ድማ ነቀኤታታት ኣሎ፡ ነቲ ዝፈሪ መድሃኒታት ናብ ዘይመዓሉኡ ብዝብል ጥርጣረ ኣብመጎ እቶም መጽናዕቲ ካብ ዘካይዱ ክኢላታት ናይቲ ላባራቶሪታት
The WHO included lopinavir/ritonavir in the international Solidarity trial.
ዉዱብ ጥዕና ዓላማት(WHO) ኣብ ተወሳኺ ዓለምለኻዊ ሎፒናቪር( lopinavir /ራይቶናቪትር( ritonavir) ገሮም እዮም።
Remdesivir was created and developed by Gilead Sciences as a treatment for Ebola virus disease and Marburg virus infections . Gilead Sciences subsequently discovered that Remdesivir had antiviral activity in vitro against multiple filo-, pneumo-, paramyxo-, and corona- viruses .
ረምደሲቪር (Remdesivir) ብ ጊልኣድ ስነ-ፍልጠታት ከም ክንክን ንሕማም ኢቦላ ቫይረስን መልከፍቲ ማርበርግ ቫይረስ ተማሂዙን ማዕቢሉን።ጊልኣድ ስነ-ፍልጠት ኣስዒቡ ኣንቲቫይራል ንጥፈት ኣብ ቪትሮ ኣንጻር ብዙሕ ፊሎ-፡ፕኑዩሞ-፡ፓራሚሶ-ን ኮሮና-ቫይረሳት ዳህሲሱ።
One issue with antiviral treatment is the development of resistance through mutations that can lead to more severe disease and transmission.
ሓደ ጉዳይ ምስ ጸረ-ቫይራል ፍወሳ ናይ ምዕባለ ተጻዋርነት ብመገዲ ልዉጠት ናብ ብዙሕ ክብድ ዝበለ ሕማም ንምትሕልላፍን ክመርሕ ዝክእል እዩ።
Some early pretrial studies suggest remdesivir may have a high genetic barrier to resistance.There are several clinical trials underway, including two conducted by Cleveland University Hospitals; one for people with moderate illness and another for those with more severe illness.
ገለ ናይ ቅድም ናይ ፕረተርያል መጽናዕቲ ከም ዝሕብሮ፡ ረምደሲቪር (remdesivir) ናይ ምጽዋር ጀነቲካዊ ሽግራት ኣለዉ ይብል። ገለ ገለ መጽናዕታት ብ ክለቨላንድ ኡኒቨርሲቲ ሆስፒታል ዝተኻየዱ ክልተ ዓይነታት ዝጠርነፈ ፡ ሓደ ነቶም ተዛማዲ ደሓን ናይ ጥዕና ኩነታት ዘልውዎም፡ ካልኣይ ድማ ነቶም ከቢድ ናይ ሕማም ሽግራት ዘለዎም።
There are three ongoing clinical trials of intravenous vitamin C for people who are hospitalized and severely ill with COVID-19; two placebo controlled (China, Canada) and one with no control (Italy).
ሰለስተ ሕክምና ፈተነታት ናይ ኢንትራቨኖስ ቫይታሚን ሲ ንኣብ ሕክምና ብ ከቢድ ሕማም ኮቪድ 19 ዘለዉ ይካየድ ኣሎ፡ ክልተ ናይ ኣእምሮ ቁጽጽር (ቻይና፣ካናዳ)፡ ሕንቲ ብዘይ ቁጽጽር (ጥልያን)።
New York State began trials for the antibiotic azithromycin on 24 March 2020.
ኣብ መጋቢት 24, 2020፡ መንግስቲ ኒው ዮርክ ፈተነታትን ጸረ-ባልዕ ኣዚትሮምሲን ጀሚሩ።
Japan's National Center for Global Health and Medicine (NCGM) is planning a clinical trial for Teijin's Alvesco (ciclesonide), an inhaled corticosteroid for asthma, for the treatment of pre-symptomatic patients infected with the novel coronavirus.
ናይ ጃፓን ሃገራዊ ማእከል ን ዓለማዊ ናይ ጥዕናን መድሃኒትን (NCGM) ሓደ ናይ ክሊኒክ ፈተነ ን ተኡጂንስ ኣልቨስኮ (ciclesonide) ፡ ናይ ኣዝማ ዝስትንፈስ ኮርቲኮስተሮኢድ፡ ን ቅድመ-ሕማም ናይ ተሕከምቲ ናይ ኮሮና-ቫይረስ ንምሕካም ፡ ክገብር ይምድብ ኣሎ፡፡
A form of angiotensin-converting enzyme 2, a Phase II trial is underway with 200 patients to be recruited from severe, hospitalized cases in Denmark, Germany, and Austria to determine the effectiveness of the treatment.
ሓደ መልክዕ ኣንግዮተንዝን ኮንቨርቲን ኢንዛይም ክልተ (angiotensin-converting enzyme 2) ካልኣይ መድረክ ፈተና 200 ተሓከምቲ ካብ ተኣፋፊ ኩነታት ሓውዮም ደነማርክ፡ ጀርመን፡ ኣውስትርያ ድማ ዕውትነት ናይቲ መድሃኒት ይገልጻ
Researchers from the Montreal Heart Institute in Canada are currently studying the role of colchicine in reducing inflammation and pulmonary complications in patients suffering from mild symptoms of COVID-19.
ኣብ ሞንትርያል ካናዳ ፡ናይ ልቢ ኢንስቲቱት ዝርከቡ ፡ ናይ መጽናዕቲ ግሩፕ፡ እዚ ሰልቺኒ (colchicine) ኣብ ምጉዳል ነድሪ ናይ ጎሮሮ ፡ ኣብቶም ብ ናይ ኮቪድ-19 ሕልኽላኽ ናይ ሕማም ዝሳቀዩ ፡ መጽናዕቲ ይገብር ኣሎ።
The study, named COLCORONA, is recruiting 6000 adults aged 40 and over who were diagnosed with COVID-19 and experience mild symptoms not requiring hospitalization.
መጽናዕቲ ኮልኮሮና (COLCORONA) ዝባሃል ፡ 6000 እኹላት ሰባት ዕድመ 40ን ልዕሊኡን ኮቪድ-19 ዝተረክቦም ይኸትብ ኣሎ።ፈኩስ ምልክታት ሕክምናዊ ፍወሳ ኣየድልዮን።
Women who are pregnant or breastfeeding or who do not have an effective contraceptive method are not eligible.
ጥኑሳት ደቂ-ኣንስትዮ ፡ ዘጥብዋ፡ ወይ ውን ዝኾነ ግቡእ መከላኸሊ ዘይጥቀማ ደቂ-ኣንስትዩ ብቁዓት ኣይኮናን።
Several anticoagulants are being tested in Italy.
ብዙሓት ጸረ-ምርጋእ ጽልዋ ዘለዎም ኣብ ሃገረ ጣልያን ይፍተኑ ኣለዉ።
Low-molecular-weight heparin is being widely used to treat patients, prompting the Italian Medicines Agency to publish guidelines on its use.
ውሑድ ዓቐን ሀፓሪን( heparin) ብሰፊሑ ኣብ ምሕካም ሕሙማት ንጥቀመሉ እዩ፣ ብመሰረት ናይ ኢጣልያ መድሃኒት ኤጀንሲ ኣገባባት ኣጠቓቅማ።
A multicenter study on 300 patients researching the use of enoxaparin sodium at prophylaxis and therapeutic dosages was announced in Italy on April 14.
ኣብ 14 ሚያዝያ ማእከላዊ መጽናዕቲ ኣብ 300 ሰባት እኖዛፕሪን ሶዲዩም ኣብ ኣቀዲምካ ምክልካልን ስነ ፈዉሲ ዓቀንን ከምዝተካየደ ይፍለጥ።
Since SARS-CoV-2 is a virus, considerable scientific attention has been focused on repurposing approved anti-viral drugs that were developed for prior outbreaks such as MERS, SARS, and West Nile virus.
ሳርስ-ኮቭ-2 (SARS-CoV-2) ቫይረስ ስለ ዝኾነ ምጡን ስነ-ፍልጠታዊ ኣቓልቦ ናብ ዳግመ ምጥቃም ዝተኣመነሎም ጸረ-ቫይረስ መድሃኒታት ኣቐዲሞም ዝማዕበሉ ቅድሚ ምስፍሕፋሕ መርስ፣ሳርስን ምዕራባዊ ናይል ቫይረስን (MERS, SARS, and West Nile virus)።
Ribavirin: ribavirin was recommended for COVID-19 treatment according to Chinese 7th edition guidelines
ሪባቭሪን (Ribavirin)፡ ብ መሰረት ናይ ቻይና 7ይ ሕታም መምርሒታት፡ ሪባቭሪን (Ribavirin)፡ ን ኮቪድ-19 ፍወሳ ክኸውን ከም ዝኽእል ተጻሒፉ ኣሎ።
Umifenovir: umifenovir was recommended for COVID-19 treatment according to Chinese 7th edition guidelines
ብመሰረት 7ይ ቻይናዊ ሕታም ኣምፈኖቪር(umifenovir) ንኮቪድ-19 ሕክምና ይምከር።
Some antibiotics that have been identified as potentially repurposable as COVID-19 treatments:
ገለ ጸረ ኣካላት ንኽንክን ኮቪድ-19 ዳግመ ዕላማ ከምዘለዎም ተፈሊጡ።
Tocilizumab (Anti-IL-6 receptor): Approved by China.
ቶሲሊዙማብ (ጸረ--IL-6 ተቀባሊ) (Tocilizumab (Anti-IL-6 receptor))፡ ብ ቻይና ዝተረጋገጸ።
Also trials in Italy and China. and see Tocilizumab#COVID-19.
ከምኡ’ውን ፈተናታት ኣብ ጥልያንን ቻይናን። ከምኡውን ርአsee Tocilizumab#COVID-19።
It is unclear yet whether conditions arising during pregnancy including diabetes, cardiac failure, hypercoagulability or hypertension might represent additional risk factors for pregnant people as they do for nonpregnant people.From the limited data available, vertical transmission during the third trimester probably does not occur, or only occurs very rarely.
ኣብ ግዜ ጥንሲ ዝለዓል ኩነታት፡ ክሳብ ሕጂ ንጹር ኣይኮነን። ከም ሽኮርያ፡ ድኻም ልቢ፡ልዑል ምርጋእ ደም፡ ጸቅጢ ደም የጠቃልል፡ ልክዕ ኣብ ዘይጥኑሳት ዘጋጥም ተወሳኺ ናይ ሓደጋ ረቋሒ ኣብ ጥኑሳት’ዉን የጋጥም እዩ። ካብቲ ዘሎ ድሩት ሓበሬታ ትኹላዊ ምምሕልላፍ ኣብ ግዜ ታሽዓይ ወርሒ ዳርጋ አየጋጥምን ወይ ሓሓሊፉ ከጋጥም ይኽእል።
There is no data yet on early pregnancy.
ክሳብ ሕጂ ናይ መጀመርያ ጥንሲ መረዳእታ የለን።
Little evidence exists to permit any solid conclusions about the nature of COVID-19 infection in pregnancy.
ዝኾነ መደምደምታ ለበዳ ኮቪድ-19 ኣብ ነፍሰጾራት መደምደምታ ንኸገብርሉ ዉሑድ ጭብጥታት እዩ ዘሎ።
A case series of 43 women from New York who tested positive for COVID-19 showed similar patterns to non-pregnant adults: 86% had mild disease, 9.3% had severe disease and 4.7% developed critical disease.
43 ደቂ ኣንስትዮ ኣብ ኒውዮርክ ብኮቩድ-19 ዝተለኽፋ ተመሳሳሊ ባህሪ ምስ ነፍሰጾራት ዘይኮና ደቂኣንስትዮ ኣርእየን። 86 ሚእታዊት ፎኪስ ሕማም ክከውን ከሎ፡ 9.3 ሚእታዊት ሓደገኛ ሕማም ክሓማ ከለዋ፡ 4.7 ሚእታዊት ድማ ኣብ ተኣፋፊ ኩነታት ነይረን።
Fetal distress was reported in two.
ዕሸላዊ ስቓይ ኣብ ክልተ ተመሓላሊፉ ኔሩ።
None of the women developed severe COVID-19 pneumonia or died.
ወልሓደ ካብተን ደቂ ኣንስትዮ ከቢድ ኮቪድ-19 ኒሞንያ ወይ ሞት ኣየራያን።
All of them had live birth pregnancies and no severe neonatal asphyxia was observed.
ኩለን ህሉዋት ቆልዑ ወሊደን፡ ዝኾነ ከቢድ ናይ ምስትናፋስ ጸገም ዘለዎ (neonatal asphyxia) ቆልዓ ድማ ኣይተረኽበን።
The samples of breast milk, amniotic fluid, cord blood and neonatal throat swab were tested for SARS-CoV-2, and all results were negative.In another study on 15 pregnant women, majority of the patients presented with fever and cough, while laboratory tests yielded lymphocytopenia in 12 patients.
እቲ ቅምሶታት ናይ ጸባ ጡብ ኣደ፡ ኣምንዮቲክ ኣሲድ፡ ናይ ዕትብቲ ደም፡ ናይ ናኦቲካል ቅምሶ፡ ን ናይ SARS-CoV-2 መርመራታት ተኻይድሎም፡ ኩሎም እቶም ውጽኢታት ድማ ኣሉታ ኢዮም ኔሮም። ኣብ ካልእ መጽናዕቲ ኣብ 15 ጥኑሳት ዝተገብረ፡ ዝበዝሓ እተን ተሓከምቲ ብ ረስኒን ሰዓልን ተታሒዘን፡ እቲ ናይ ላባራቶሪ ውጽ ኢት ግን ናይ ልይምፎቲሶፐንያ (lymphocytopenia) ውጽኢት ተራእይሉ።
Computed tomography findings of these patients were consistent with previous reports of non-pregnant patients, consisting of ground-glass opacities at early stage.
ናይዞም ሕማማት ዝተቀመረ ቶሞግራፊያዊ ርክባ ምስ ናይ ቅድም ናይ ዘይነብሰ-ጾር ሕሙማት ጸብጻብ ፡ናይ ባይታ-ጥርሙዝ ግርደት ኣብቲ መጀመርያ ደረጃ ዝሓዘ ይሳማማዕ ኔሩ።
Follow-up images after delivery showed no progression of pneumonia.Media reports indicate that over 100 women with COVID-19 might have delivered, and in March 2020, no maternal deaths were reported.
ስዒቡ ዝመጸ መግለጺታት ምዕባለ ኒሞንያ ድሕሪ ምሕራሰን የለን። ማዕከናት ዜና 100 ደቂ ኣንስትዮ ኮቪድ-19 ዝተለኽፋ ይሕብር።ኣብ መጋቢት 2020 ድማ ወልሓደ ሞት ናይ ኣደ ኣይተመዝገበን።
Their guidelines thus advise that any pregnant person admitted to hospital with a COVID-19 infection should receive at least 10 days of prophylactic low-molecular-weight heparin after being discharged from the hospital.
እዚ መምርሖታት ከም ዝሕብሮን ዝመኽሮን፡ ሓንቲ ጥንስቲ ኣደ ብሰንኪ ኮቪድ-19 ናብ ሆስፒታል ዝኣተወት፡ ብውሑዱ 10 መዓልታት ውሑድ-ሞለኩላር-ክንደት ዘለዎ ሀፓሪን መከላኸሊ-ሕማም ኵአስድ ኣለዎ፡ ካብ ሕክምና ድሕሪ ምልቃቁ
There are no data yet concerning the implications of COVID-19 infections for labour.
ናተን ብ ንቡር ጻዕሪ ዝሓርሳ ኣዴታት ዝኾነ ኣፋፍኖት ናይ ኮቪድ-19 ምምሕልላፍ ከምዝተራእየ ዝሕብር ጸብጻብ የለን።
One infant girl born to a mother with COVID-19 had elevated IgM levels two hours after birth, suggesting that she had been infected in utero and supporting the possibility of vertical transmission in some cases.
ሓንቲ ካብ ኮቪድ-19 ዘለዋ ኣደ ዝተወልደት ናጽላ ህጻን፡ ድሕሪ 2 ሰዓት ምውላዳ ነቲ IgM ዓቀን ክብ ከም ዘበለቶ ተፈሊጡ፡ እዚ ድማ ኣብ ማህጸን እንከላ ተለኺፋ ክትከውን ከም እትኽእልን ናይ ትኹል ምምሕልላፍ ተኽእሎ ከም ዘሎን ዘነጽር ኢዩ።
A small study involving 6 confirmed COVID-19 mothers showed no indication of SARS-COV-19 in their newborns' throats or serum but antibodies were present in neonatal blood sera samples, including IgM in two of the infants.
ሓንቲ ንኢሽተይ መጽናዕቲ ን 6 ብ ኮቪድ-19 ዝተለኽፋ ኣዴታት ዘሳተፈት፡ ኣብ ውሉደን ጎሮሮ ወይ ሰሩም ዝኾነ ምልክታት ናይ SARS-COV-19 ኣይተራእየን፡ እንተኾነ ግን ኣብቲ ናይ ቅምሶ ናይ ኒኦናታል ደም ጸረ-ነፍሳታ ኔሮም፡ IgM ዘጠቃለለ ኣብ ክልተ ናጽላታት ጸረ-ነፍሳታ ኔሮም
This is not usually passed from mother to fetus so further research is required to know whether the virus crossed the placenta or whether placentas of women in the study were damaged or abnormal.
እዚ ካብ ኣደ ናብ ዕሸል ዝሓልፍ ዓይነት ሕማም ኣይኮነን፡ እንተኾነ እቲ ቫይረስ ነቲ መዳሕንቲ ሓሊፉ ከይከውን ወይ`ውን እቲ ፕላሰንታ ናይ ኣደ ዘይጥዑይ ኔሩ ከይከውን፡ ዓሚቕ መጽናዕቲ ክካየድ ኣለዎ።
Since COVID-19 shows similarities to SARS-CoV and MERS-CoV, it is likely that their effect on pregnancy are similar.
ኮቪድ-19 ክሳብ ምስ ሳርስ-ኮቭን መርስ-ኮቭን ምምስሳል ዘርኣየ፡ብተመሳሳሊ እቲ ጽልዋ ኣብ ጥንሲ ሓደ ዓይነት እዩ።
Four of seven had first trimester miscarriage, two of five had fetal growth restriction in the second trimester, and four of five had preterm birth.
መጀመርያ ሰለስተ ወርሒ፡ኣርባዕተ ኣብ ለዕሊ ሸውዓተ ምብርዓን፡ካለኣይ ሰለስተ ወርሒ ክልተ ኣብ ለዕሊሓሙሽተ ምዕጋት ዕሸላዊ ዕብየትን ኣርባዕተ ኣብ ልዕሊ ሓሙሽተ ሞት ቅድሚ ምውላድን ኔርዎ።
None of the newborns were infected with SARS-CoV.
ሓደ ካብ ሓደሽቲ ዝተወልዱ ብ SARS-CoV ተለኺፉ።
A report of ten cases of MERS- CoV infection in pregnancy in Saudi Arabia showed that the clinical presentation is variable, from mild to severe infection.
ዓሰርተጉዳያት መርስኮቭ (MERS- CoV) ለበዳ ኣብ ነፍሰጸሮራት ኣብ ሱዕዲ ዓረብ ዝተፈላለየ መግለጺታት ካብ ዝፎኮሰ ክሳብ ዝኸበደ ተራእዩ።
The outcome was favorable in a majority of the cases, but the infant death rate was 27%.A recent review suggested that COVID-19 appeared to be less lethal to mothers and infants than SARS and MERS but that there may be an increased risk of preterm birth after 28 weeks' gestation.
ኣብ ዝበዝሐ ጉዳይ እቲ ውጽኢት ዘዐግብ እዩ ነይሩ፡ ግን ናይ ነኣሽቱ ሞት 27% ሚእታዊት ነይሩ ሓደ ናይ ቀረባ መጽናዕቲ ኣብ ኮቪድ-19 ኣብ ኣዴታትን ህጻናትን ካብ በዓል ሳርስን መርስን ተጓዳእነቱን ቑሩብ ክረአ ኮሎ ግና ሓደጋ ናይ ምውሳኽ ተኽእሎ ኣሎ፡ ኣብ ቕድሚ ግዜ ሕርሲ ድሕሪ 28 ከምኡውን #39 ናይ ጥንሲ ሳምንታት
The World Health Organization and Centers for Disease Control and Prevention of the United States advises pregnant women to do the same things as the general public to avoid infection, such as covering cough, avoid interacting with sick people, cleaning hands with soap and water or sanitizer.
ውዱብ ዓለማዊ ጥዕና (WHO) ማእከል ሙቁጽጻርን ምክልኻልን ኣሜርካ ንነብሰጾራት ከምቶም ካልኦት ሰባት ነብሰን መታን ክከላኸላ፣ ክስዕላ ከለዋ ክሽፈና ከምዘለወን ፡ ምስ ዝሓመሙ ሰባት ርክብ ከወግዳ ከም ዘለወን፡ ኣእዳወን ብሳምና ወይ ሳይኒታይዘር ክሕጸባ ከም ዘለወን ይመኽሩ።
A survey conducted in Shanghai among pregnant women in different trimesters of pregnancy identified a strong demand for online access to health information and services.
ኣብ መንጎ እተን ዝተፈላላየ ደረጃ ናይ ጥንሲ ዘለወን ደቂ-ኣንስትዮ ብዝተገብረ መጽናዕቲ፡ ነቲ ብ ኦንላይን ዝርከብ ናይ ጥዕና ሓበሬታ ኣዝዩ ብዙሕ ተጠቃምነት ከምዝገበራ ፡ ኣብ ሻንጋይ ዝተገብረ መጽናዕቲ ሓቢሩ
People expecting their first baby were more willing to have online consultation and guidance than who had previously given birth.The RCOG and RCM recommend that in-person appointments be deferred by 7 days after the start of symptoms of COVID-19 or 14 days if another person in the household has symptoms.
እቶም ናይ መጀመርያ ውላዶም ዝጽበዩ ሰባት ን ናይ ኦንላይን ምኽሪን ሓበሬታን ኣዝዮም ክፉታት ኮይኖም ኢዮም ምስቶም ቅድሚ ሕጂ ውላድ ዝነበሮም እቶም RCOG ን RCMን ነቲ ናይ ውልቂ ሰባት ቆጸራታት ብ 7 መዓልታት ክናዋሕ ይኽእል ኢዩ፡ እዚ ድማ ድሕሪ ምልክታት ናይ ኮቪድ-19 ምራዩ ወይውን ኣብቲ ዝነብረሉ ገዛ ዝኾነ ልኹፍ ናይ ኮቪድ-19 ምስ ዝህሉ ናይ ድማ ድሕሪ 14 ማዓልታት
Fever subsequently developed in three asymptomatic patients.
ረስኒ ኩሉ ግዜ ኣብ ሰለስተ ምልክት ሕማም ዘይርእዩ ሰባት ይምዕብል።
One patient who had tested negative subsequently became symptomatic postpartum and tested positive three days after the initial negative test.
ሓደ ሕሙም ተመርሚሩ ኣሉታ ድሕሪ ምጽንሑ፡ድሕሪ ሰለስተ ማዓልቲ ናይ መጀመርያ ኣሉታዊ መርመራ ፡ምልክት ናይ ድሕረ-ግልግል ኣወንታዊ ውጽኢት ጸኒሕዎ።
The doctors conducting the screening recommended that in order to reduce infection and allocate PPE, due to high numbers of patients presenting as asymptomatic, universal screening of pregnant patients should be conducted.
ሓካይም እስኪሪኒን ዘካይዱ ንምውሓድ ለበዳን ምምራሕ ፒፒኢን(PPE)፡ ካብ ብዝሒ ቁጽርታት ተሓከምቲ ነጻ ምኻኖም ፡ ኣድማሳዊ እስክሪን(SCREENING) ነፍሰጾራት ተሓከምቲ ከካይድ እዩ
They also suggest that people with suspected or confirmed COVID-19 should have continuous electronic fetal monitoring.
ከምኡውን እቶም ኮቪድ-19 ዝሓዞምን ክሕዞም ይኽእል ተባሂሎም ዝተጠርጠሩን ቀጻሊ ናይ ኤለክትሮኒክ ናይ ሞት ምቁጽጻር ክገብሩ ክኽእሉ ኣለዎም ኢሎም ኣማኺሮም።
The use of birthing pools is not recommended for suspected or confirmed cases of COVID-19 due to the risk of infection via faeces.
ሓደ ልኹፍ ናይ ኮቪድ-19 ናይ መወልዳን-ባኞ ክጥቀም ልቦናዊ ወይ ጽቡቕ ኣይኮነን፡ ምኽንያት እቲ ሕማም ብ ናይ ቀልቀል ተረፍ-መረፍ ክመሓላለፍ ተኽእሎታት ስለ ዘለዎ
In the UK, official recommendations state that precautionary separation of a mother and a healthy baby should not be undertaken lightly and that they should be kept together in the postpartum period where neonatal care is not required.Literature from China recommended separation of infected mothers from babies for 14 days.
ኣብ ዓባይ ብሪጣንያ ቅድመ ጥንቃቐ ድሕሪ ናይ ሕርሲ ግዜ ዘሎን ምፍላይ ናይ ኣደን ጥዑይ ህጻንን ብቀሊል ክረአ የብሉን።ንጽላዊ ምክንኻን ኣየድልን እዩ።ጽሑፋዊ መግለጺ ካብ ቻይና፡ምፍላይ ዝተለኽፋ ኣዴታት ካብ ህጻናት ን 14 መዓልታት ክህሉ ገሊጾም።
In the US there is also the recommendation that newborns and mothers should be temporarily separated until transmission-based precautions are discontinued, and that where this is not possible the newborn should be kept 2 metres away from the mother.
ኣብ ሕብራት መንግስታት ኣሜሪካ፡ ዕሸላትን ኣዴታትን ንኸይትሓላለፉ ንግዜኡ ክፈላለዩ ምሕጽንታ ተዋሂቡ።ብመሰረት ቅድመ መጠንቀቅታ ምቁራጹ፡ እዚ እንተዘይተኻኢሉ እቲ ዕሸል ካብ ኣደ 2 ሜትሮ ክርሕቅ ኣሎዎ።
b'COVID-19 surveillance involves monitoring the spread of the coronavirus disease in order to establish the patterns of disease progression.
ናይ ኮቪድ-19 ምክትታላት ንምቁጽጻር ምስፍሕፋሕ ኮረና ቫይረስ ሕማም ይጥቕልል፣ ንምምስራት መርኣያ ምዕባለ እቲ ሕማም።
The World Health Organization (WHO) recommends active surveillance, with focus of case finding, testing and contact tracing in all transmission scenarios.
ዓለምለኻዊ ዉድብ ጥዕና( WHO) ኣብ ኣድህቦ ርክባት ኩነት፡ ፈተነ ንዝሓመሙ ምርካብ ኣብ ኩሉ ናይ ምትሕልላፍ ተርእዩ ንጡፍ ጽኑዕ ሓለዋ ክህሉ ሓሳብ ሂቡ።
COVID-19 surveillance is expected to monitor epidemiological trends, rapidly detect new cases, and based on this information, provide epidemiological information to conduct risk assessment and guide disease preparedness.
ምክትታል ናይ ኮቪድ-19ነቲ ናይ አፒድዮሞሎጂካል ምንቕስቓሳት ክቆጻጸሮ፡ ቅልጡፍ ምልላይ ናይ ሓደሽቲ ሕሙማት፡ ከምኡ’ውን ኣብዚ ሓበሬታ ብምምርካስ ናይ አፒድዮሞሎጂ ሓበሬታ ን ናይ ሓደገኝነት ሕማምን ምድላዋትን ፡ቅመራን መምርሒን ፡ ከካይድ ትጽቢት ይግበረሉ፡፡
Syndromic surveillance is done based on the symptoms of an individual that corresponds to COVID-19.
ስይንድሮሚክ ምክትታል ፡ በቲ ምልክታት ናይቲ ኮቪድ-19 ሓሚሙ ወይ ተለኺፉ ዘሎ ምርኩስ ብምግባር ኢዩ ዝካየድ
As of March 2020, the WHO recommends the following case definitions:
ካብ መጋቢት 2020 ዓለማዊ ማሕበር ጥዕና ነዞም ዝስዕቡ መግለጺ ጉዳያት ይመክር
Probable case : "A suspect case for whom testing for the COVID-19 virus is inconclusive" OR "a suspect case for whom testing could not be performed for any reason".
ጉዳይ ተኽእሎ፡ ንሓደ ጥርጡር ኮቪድ-19 መርመራ ዘየዕግብ እዩ ወይ ከኣ ብዝኾነ ምኽንያት ኣይገብርን እዩ።
Confirmed case: "A person with laboratory confirmation of COVID-19 infection, irrespective of clinical signs and symptoms".
ዝተለኽፈ ሰብ፡ ``ኣብ ላባራቶርይ ዝተረጋገጸ መልከፍቲ ናይ ኮቺድ-19 መልከፍቲ፡ እቲ ምልክታቱን ትርኢቱን ብዘይገድስ።
Direct physical contact with a probable or confirmed case;
ቀጥታዊ ርክብ ምስ ዝሓመሙ ወይ ተርእዮታት ሕማም ዘለዎ ጉዳይ
Direct care for a patient with probable or confirmed COVID-19 disease without using proper personal protective equipment;
ቀጥታዊ ክንክን ን ተሓከምቲ ምስ ኮቪድ-19 ሕማም ንዘለዉ፡ ብዘይ መከላኸሊ መሳርሒ
Other situations as indicated by local risk assessments".WHO recommends reporting of probable and confirmed cases of COVID-19 infection within 48 hours of identification.
ካልእ ኩነት ከምዘመልክቶ፡ ገምጋም ናይ ውሽጢ ሓደጋታት ውድብ ጥዕና ዓለም WHO ፡ ብ ኮቪድ-19 ዝተለኽፉ ኣብ ውሽጢ 48 ሳዓታት ብዝተኻእለ ጸብጻብ ክሓልፍ ዓለምለኻዊ ውድብ ጥዕና ተላብዮም።
The countries should report on a case-by-case basis as far as possible, but in case of limitation in resources, aggregate weekly reporting is also possible.
ብዝተኻእለ፡ ሃገራት ነቲ ዝተረኽበ ኩነት ሓደ ብሓደ ጸብጻብ ክህባ ኣለወን። ግና'ኸ ሕጽረታት ስለ ዝህሉ፡ ብጥርኑፍ ናይ ሰሙን ክሕበር ይካኣል እዩ።
Some organizations have created crowdsourced apps for syndromic surveillance, where people can report their symptoms to help researchers map areas with concentration of COVID-19 symptoms.
ገለ ገለ ማሕበራት ናይ ኮምፒተር ፕሮግራም እድእልየኝ እለው፡ እዚ ድማ ሰባት ዘለዎም ናይ ሕማም ምልክታት ናብ ናይ መጽናዕቲ ጉጅለ ጸብጻባት ክህቡን፡ እቶም መጽናዕቲ ዝገብሩ ድማ ነዚ ብምጥቓም ኣየናይ ከባቢታት በዚ ኮቪድ-19 ኣዝዩ ተሃስዩ ከም ዘሎ ንክፈልጡን ይሕግዞም
Virological surveillance is done by using molecular tests for COVID-19.
ቪሮሎጂካላዊ ጽኑዕ ክትትል ሞለክዩላዊ መርመራ ብምጥቃም ኮቪድ19 ተመርሚሩ።
WHO has published resources for laboratories on how to perform testing for COVID-19.
ውድብ ጥዕና ዓለም (WHO) ን ኮቪድ-19 ክምርመረሉ ዝኽእል ናይ ላባራቶሪ መሳርሒታት ን ኣገባባትን ኣብ ጽሑፉ ሓቲሙ ኣሎ።
In the European Union, laboratory confirmed cases of COVID-19 are reported within 24 hours of identification.
ኣብ ኤሮፓዊ ሕብረት ላባራቶሪ ምርምር ብ ኮቪድ-19 ዝተለኽፉ ሰባት ኣብ ውሽጢ 24 ሰዓት ይሕብር
At least 24 countries have established digital surveillance of their citizens.
ብዉሑዱ 24 ሃገራት ፡ ጽኑዕ ዝኾነ መከታተሊ ን ዜጋታተን ወይ ህዝበን ሰሪሐን ኣለዋ።
The digital surveillance technologies include apps, location data and electronic tags.
ሙዕቡል መራይዩ ቴክኖሎጂ ኣፕሊኬሽን ዘለኻዮ ቦታ ኤሌትሮኒካዊ ላግባ (ELETRONIC TAGS)
The Center For Disease Control and Prevention in USA tracks the travel information of individuals using airline passenger data.
ማእከላይ ምቁጽጻር ሕማምን ምክልኻልን ሕቡራት መንግስትታት ኣሜሪካ፡ናይ መጎዓዝያ ሓበሬታ፡ውልቀሰባት ተጉዓዝቲ መንገዲ ኣየር ብምጥቃም ጭብጢ ረኺቦም።
In Hong Kong, authorities are requiring a bracelet and an app for all travellers.
ኣብ ሆንግኮንግ፡መዚ ባዓል ስልጣን ካብ ኩሎም ተጋዓዝቲ በናጅርን መወከስን ይጠልብ።
A GPS app is used to track the locations of individuals in South Korea to ensure against quarantine breach, sending alerts to the user and to authorities if people leave designated areas.
እቲ ናይ GPS ናይ ኮምፒተር ፕሮግራም ፡ ነቶም ነበርቲ ናይ ደቡብ ኮርያ ዘለዉዎ ቦታ ከም መኸተሊ ይጠቅም ኢዩ፡ እዚ ድማ ነቲ ናይ ምውሻብ ደረት መረጋገጺ ክጠቅም ይኽእል፡ ወይውን ዝኾነ መጠንቀቅታታት ነቶም በዓል መዚታት፡ ኣብ ግዜ ሕጊ ምጥሓስ፡ ይበጽሖም
In Singapore, individuals have to report their locations with photographic proof.
ኣብ ሲንጋፖር ነፍስወከፍ ሰብ ዘለዎ ቦታ ብስእሊ ዝተሰነየ ጭብጢ የቅርብ።
Thailand is using an app and SIM cards for all travelers to enforce their quarantine.
ታይላንድ ንኩሎም ገያሾኣ ዉሸባ ምእንቲ ክትግድድ፡ ኣፕን ሲም ካርድን ትጥቀም ኣላ።
Human rights organizations have criticized some of these measures, asking the governments not to use the pandemic as a cover to introduce invasive digital surveillance.
ተሓላቒ ሰብኣዊ መሰላት ፡ መንግስታት ነዚ ለበዳ ከም መመኽነይታ ተጠቂመን ዘይግቡእ ምክትታል ወይ ድማ ዲጂታል ሓለዋ ከይገብሩ ብትሪ ኮኒኑን ኣጠንቂቁን ይርከብ።
b'A COVID-19 vaccine is a hypothetical vaccine against coronavirus disease 2019 (COVID-19).
ክታበት b"A ኮቪድ-19 ጽንሰ-ሓሳባዊ ክታበት ኣንጻር ሕማም ኮሮናቫይረስ 2019 (ኮቪድ-19) እዩ።
Although no vaccine has completed clinical trials, there are multiple attempts in progress to develop such a vaccine.
ወላካ ክሳብ ሕጂ ናይ ክሊኒክ ፈተናታት ሓሊፉ ዝተወድአ ክታበት ኣይሃሉ፡ ክሳብ ሕጂ ግን ኣዝዮም ብዙሓት ፈተነታት ኣብ ምምዕባል ዘለዉ ናይ ክታበት መስርሓት ይካየዱ ኣለዉ።
In late February 2020, the World Health Organization (WHO) said it did not expect a vaccine against SARS-CoV-2, the causative virus, to become available in less than 18 months.
ኣብ መወዳእታ ለካቲት 2020 ዓለምለኻዊ ዉዱብ ጥዕና (WHO) ክታበት ኣንጻር SARS-CoV-2እቲ ጠንቃዊ ቫይረስ ኣብ 18 ኣዋርሕ ዘይመልእ ክርከብ ኣይተጸበናን ኢሉ።
Five vaccine candidates were in Phase I safety studies in April.
ኣብ መጋቢት ፡ ሓሙሽተ ካብቶም ናይ ክታበት ሕጹያት ወይ ተወዳደርቲ ኣብ ናይ ደረጃ I ኔሮም።
COVID-19 was identified in December 2019.
ኮቪድ-19 ኣብ ታሕሳስ 2019 ተረኺቡ።
A major outbreak spread around the world in 2020, leading to considerable investment and research activity to develop a vaccine.
ኣብ 2020 ቀንዲ ለብዒ ናብ ሙሉእ ዓለም ተዘርጊሑ፡ብብዝሒ ምውፋር ንመጽናዕታዊ ንጥፈታትን ክታበት ምምዕባልን ይመርሕ።
Many organizations are using published genomes to develop possible vaccines against SARS-CoV-2.
ብዙሓት ዉዱባት ዝተሓትመ ጀኖም ንምምዕባል ክታበት ኣንጻር SARS-CoV-2 ይጥቀሙ ኣሎዉ።
Stated in April, imperatives of the CEPI initiative for vaccine development are speed, manufacturing capacity, deployment at scale, and global access.
ኣብ ሚያዝያ ከም ዝተጠቅሰ ዘሀውኽ ጉዳይ ሲ ፒ ኢ (CEPI) መበገሲ ናይ ምዕባለ ክታበት ቅልጡፍ ዕብየት፡ መስርሕ ክእለት፡ ምዉፋር ዓቅሚ ዓለማዊ ዝርግሐ ኣርእዩ እዩ።
In April, CEPI scientists reported that 10 different technology platforms were under research and development during early 2020 to create an effective vaccine against COVID-19.
ኣብ ሚያዝያ CEPI ተመራመርቲ 10 ዝተፈላለዩ ቴክኖሎጂ ባይታታት ኣብ ምርምርን ምዕባለን 2020 ውጺእታዊ ክታበት ኮቪድ-19 ከምዘለው ሓቢሮም ነይሮም።
Major platform targets advanced into Phase I safety studies include:
እቲ ቀንዲ መድረኽ ሸቶ ኣብ ዝበለጸ ናይ ገጽ ⵏ ዉሕስ መጽናዕትታት የማእክል።
nucleic acid (DNA and RNA) (Phase I developer and vaccine candidate: Moderna, mRNA-1273)
ኒክሊክ ኣሲድ (DNA ን RNAን)(ገጽ 1 ምምዕባል ናይ ክታበት ምውድዳር፡ ሞደርና፡ mRNA-1273)
viral vector (Phase I developer and vaccine candidate: CanSino Biologics, adenovirus type 5 vector)
ቫይረሳዊ ቨክቶር (ገጽ 1 ኣማዕባሊን ናይ ክታበት ውድድርን፡ ካንሲኖ ባዮሎጅካዊ፡ ኣደኖ-ቫይረስ ዓይነት 5 ቨክቶር)
As reported by CEPI scientists in April, 115 total vaccine candidates are in early stages of development, with 78 confirmed as active projects (79, according to the Milken Institute), and 37 others announced, but with little public information available (presumed to be in planning or being designed).
ኣብ ሚያዝያ ብ CEPI ሰነ-ፍልጠታውያን ከምዝሓበርዎ ሓፈሻዊ ድምር 115 ሕጹያት ክታበት ኣብቲ መጀመርያ ደረጃ ናይ ምዕባለ ኣለዉ። እቶም 78 ንጥፋት ፕሮጀክት እዮም(ብመሰረት ሚልከን ትካል ከኣ 79)።ከምኡዉን ካልኦት 37 ተሓቢሩ፡ ግን ምስ ዉሑድ ህዝባዊ ሓበሬታ ዝርከቦ።
A Phase I-II trial conducts preliminary safety and immunogenicity testing, is typically randomized, placebo-controlled, and at multiple sites, while determining more precise, effective doses.
እቲ ደረጃ ናይ I-II ፈተነታት ፡ ናይ መጀመርታ ውሕስነታትን ናይ ምክልኻል ዓቅሚን ፈተነ ይገብር፡ እዚ ድማ ብዘይስሩዕ ፡ ክኸውን ይኽእል፡ ሰንጋሊ-ፈውሲ መቆጻጸሪ፡ ከምኡውን ዝተፈላለየ ቦታታት ዘጠቃልል ኢዩ፡ ኣዝዩ ፍሉጥ ዓቀን ከም መፈተንታ ድማ ይወሃብ
Phase III trials typically involve more participants, including a control group, and test effectiveness of the vaccine to prevent the disease, while monitoring for adverse effects at the optimal dose.
ገጽ ⵏⵏⵏ ፈተናታት ብባህሪኡ ብዙሓት ተሳተፍቲ የጣቓልል፡ ጉጅለ ተቆጻጻሪ የማእክል። እዚ ንናይ ክታበት ሕማም ክከላኸል ኣድማዕነት ይፍትን፡ ኣብዚ ግዜዚ ንናይ ኣሉታ ጽልዋ ኣብቲ ዝላዓለ ዓቀን ፈውሲ ይቆጻጸር።
Of 79 vaccine candidates in active development (confirmed as of early April 2020), 74 were not yet in human evaluation (still in "preclinical" research).
ካብ 79 ሑጹያት ናይ ክታበት (ኣብ መጀመርታ ሚያዝያ 2020) 74 ኣብ ደቂሰባት ገምጋም ኣይበጽሑን(ኣብ ቅድመ ምርምር እዮም ዘለዉ)።